{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:49:43Z","timestamp":1793663383733,"version":"4.5.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R44 DA044053"],"award-info":[{"award-number":["R44 DA044053"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI027757"],"award-info":[{"award-number":["AI027757"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13722-019-0139-3","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T13:04:11Z","timestamp":1552482251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence"],"prefix":"10.1186","volume":"14","author":[{"given":"Margo E.","family":"Godersky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Saxon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph O.","family":"Merrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Samet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane M.","family":"Simoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,13]]},"reference":[{"key":"139_CR1","unstructured":"Substance Abuse and Mental Health Services. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health. HHS Cent Behav Health Stat Qual Subst Abuse Ment Health Serv Adm; 2017 (No. SMA 17-5044):86."},{"key":"139_CR2","unstructured":"Centers for Disease Control and Prevention. National Center for Injury Prevention and Control. Drug Overdose Death Data; 2017. \n                    https:\/\/www.cdc.gov\/drugoverdose\/data\/statedeaths.html\n                    \n                  . Accessed 16 Mar 2018."},{"issue":"9651","key":"139_CR3","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/S0140-6736(08)61311-2","volume":"372","author":"BM Mathers","year":"2008","unstructured":"Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. The Lancet. 2008;372(9651):1733\u201345.","journal-title":"The Lancet"},{"key":"139_CR4","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. In: Cochrane database of systematic reviews; 2014. \n                    http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/14651858.CD002207.pub4\/abstract\n                    \n                  . Accessed 26 Sep 2017.","DOI":"10.1002\/14651858.CD002207.pub4"},{"issue":"2","key":"139_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/add.13193","volume":"111","author":"M Pierce","year":"2016","unstructured":"Pierce M, Bird SM, Hickman M, Marsden J, Dunn G, Jones A, et al. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. Addiction. 2016;111(2):298\u2013308.","journal-title":"Addiction"},{"issue":"5","key":"139_CR6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2105\/AJPH.2012.301049","volume":"103","author":"RP Schwartz","year":"2013","unstructured":"Schwartz RP, Gryczynski J, O\u2019Grady KE, Sharfstein JM, Warren G, Olsen Y, et al. Opioid agonist treatments and heroin overdose deaths in baltimore, Maryland, 1995\u20132009. Am J Public Health. 2013;103(5):917\u201322.","journal-title":"Am J Public Health"},{"issue":"8","key":"139_CR7","first-page":"CD004145","volume":"10","author":"L Gowing","year":"2011","unstructured":"Gowing L, Farrell MF, Bornemann R, LE Sullivan, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;10(8):CD004145.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"139_CR8","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1111\/add.12682","volume":"109","author":"S Nolan","year":"2014","unstructured":"Nolan S, Lima VD, Fairbairn N, Kerr T, Montaner J, Grebely J, et al. The impact of methadone maintenance therapy on heptatis c incidence among illicit drug users. Addict Abingdon Engl. 2014;109(12):2053\u20139.","journal-title":"Addict Abingdon Engl"},{"issue":"12","key":"139_CR9","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1001\/jamainternmed.2014.5416","volume":"174","author":"JI Tsui","year":"2014","unstructured":"Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C Virus infection in young adult injection drug users. JAMA Intern Med. 2014;174(12):1974\u201381.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"139_CR10","doi-asserted-by":"publisher","first-page":"326","DOI":"10.5694\/mja13.00153","volume":"201","author":"B White","year":"2014","unstructured":"White B, Dore GJ, Lloyd AR, Rawlinson WD, Maher L. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study. Med J Aust. 2014;201(6):326\u20139.","journal-title":"Med J Aust"},{"key":"139_CR11","unstructured":"Center for Substance Abuse Treatment. Clinical Guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). (SAMHSA\/CSAT Treatment Improvement Protocols); 2004. \n                    http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64245\/\n                    \n                  . Accessed 23 Oct 2017."},{"key":"139_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jsat.2015.06.010","volume":"60","author":"CT LaBelle","year":"2016","unstructured":"LaBelle CT, Han SC, Bergeron A, Samet JH. Office-based opioid treatment with buprenorphine (OBOT-B): statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers. J Subst Abuse Treat. 2016;60:6\u201313.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"139_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/ADM.0b013e3181cc9610","volume":"4","author":"PT Korthuis","year":"2010","unstructured":"Korthuis PT, Gregg J, Rogers WE, McCarty D, Nicolaidis C, Boverman J. Patients\u2019 reasons for choosing office-based buprenorphine: preference for patient-centered care. J Addict Med. 2010;4(4):204\u201310.","journal-title":"J Addict Med"},{"key":"139_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","volume":"160","author":"BJH Yarborough","year":"2016","unstructured":"Yarborough BJH, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA. Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis. Drug Alcohol Depend. 2016;160:112\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"139_CR15","volume-title":"Adherence to long-term therapies: evidence for action","author":"World Health Organization","year":"2003","unstructured":"World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003."},{"key":"139_CR16","first-page":"CD000011","volume":"2","author":"RB Haynes","year":"2000","unstructured":"Haynes RB, Montague P, Oliver T, McKibbon KA, Brouwers MC, Kanani R. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2000;2:CD000011.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"139_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0738-3991(78)80033-0","volume":"1","author":"DL Sackett","year":"1978","unstructured":"Sackett DL, Haynes RB, Gibson ES, Taylor DW, Roberts RS, Johnson AL. Patient compliance with antihypertensive regimens. Patient Couns Health Educ. 1978;1(1):18\u201321.","journal-title":"Patient Couns Health Educ"},{"issue":"11","key":"139_CR18","first-page":"CD000011","volume":"20","author":"R Nieuwlaat","year":"2014","unstructured":"Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;20(11):CD000011.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"139_CR19","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jana.2017.02.007","volume":"28","author":"J Barroso","year":"2017","unstructured":"Barroso J, Leblanc NM, Flores D. It\u2019s not just the pills: a qualitative meta-synthesis of HIV Antiretroviral Adherence Research. J Assoc Nurses AIDS Care. 2017;28(4):462\u201378.","journal-title":"J Assoc Nurses AIDS Care"},{"issue":"6","key":"139_CR20","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11908-008-0083-y","volume":"10","author":"JM Simoni","year":"2008","unstructured":"Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep. 2008;10(6):515\u201321.","journal-title":"Curr Infect Dis Rep"},{"issue":"3","key":"139_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1465-3362.2010.00283.x","volume":"30","author":"B Larance","year":"2011","unstructured":"Larance B, Degenhardt L, Lintzeris N, Winstock A, Mattick R. Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug Alcohol Rev. 2011;30(3):236\u201345.","journal-title":"Drug Alcohol Rev"},{"issue":"5","key":"139_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","volume":"8","author":"MR Lofwall","year":"2014","unstructured":"Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8(5):315\u201326.","journal-title":"J Addict Med"},{"key":"139_CR23","first-page":"1","volume":"10","author":"JI Tsui","year":"2017","unstructured":"Tsui JI, Burt R, Thiede H, Glick SN. Utilization of buprenorphine and methadone among opioid users who inject drugs. Subst Abuse. 2017;10:1\u20136.","journal-title":"Subst Abuse"},{"key":"139_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jsat.2017.04.017","volume":"78","author":"SR Kenney","year":"2017","unstructured":"Kenney SR, Anderson BJ, Bailey GL, Stein MD. The relationship between diversion-related attitudes and sharing and selling buprenorphine. J Subst Abuse Treat. 2017;78:43\u20137.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"139_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1056\/NEJMoa055255","volume":"355","author":"DA Fiellin","year":"2006","unstructured":"Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O\u2019connor PG, et al. Counseling plus buprenorphine\u2013naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365\u201374.","journal-title":"N Engl J Med"},{"issue":"12","key":"139_CR26","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","volume":"174","author":"DA Fiellin","year":"2014","unstructured":"Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O\u2019Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947\u201354.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"139_CR27","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/ajad.12325","volume":"25","author":"S Kumari","year":"2016","unstructured":"Kumari S, Manalai P, Leong S, Wooditch A, Malik M, Lawson WB. Factors associated with non-adherence to Buprenorphine-naloxone among opioid dependent African\u2013Americans: a retrospective chart review. Am J Addict. 2016;25(2):110\u20137.","journal-title":"Am J Addict"},{"issue":"4","key":"139_CR28","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jsat.2009.05.003","volume":"37","author":"JM Soeffing","year":"2009","unstructured":"Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009;37(4):426\u201330.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"139_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1046\/j.1360-0443.2001.9656834.x","volume":"96","author":"PG Barnett","year":"2001","unstructured":"Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction. 2001;96(5):683\u201390.","journal-title":"Addiction"},{"issue":"1","key":"139_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/10550887.2011.642758","volume":"31","author":"A Fareed","year":"2012","unstructured":"Fareed A, Vayalapalli S, Casarella J, Drexler K. Effect of buprenorphine dose on treatment outcome. J Addict Dis. 2012;31(1):8\u201318.","journal-title":"J Addict Dis"},{"issue":"4","key":"139_CR31","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.jfda.2013.09.037","volume":"21","author":"AJ Saxon","year":"2013","unstructured":"Saxon AJ, Hser Y-I, Woody G, Ling W. Medication-assisted treatment for opioid addiction: methadone and buprenorphine. J Food Drug Anal. 2013;21(4):S69\u201372.","journal-title":"J Food Drug Anal"},{"issue":"9","key":"139_CR32","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.5588\/ijtld.14.0923","volume":"19","author":"RS Garfein","year":"2015","unstructured":"Garfein RS, Collins K, Mu\u00f1oz F, Moser K, Cerecer-Callu P, Raab F, et al. Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study. Int J Tuberc Lung Dis. 2015;19(9):1057\u201364.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"3","key":"139_CR33","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3201\/eid2203.151620","volume":"22","author":"A Story","year":"2016","unstructured":"Story A, Garfein RS, Hayward A, Rusovich V, Dadu A, Soltan V, et al. Monitoring therapy adherence of tuberculosis patients by using video-enabled electronic devices. Emerg Infect Dis. 2016;22(3):538\u201340.","journal-title":"Emerg Infect Dis"},{"key":"139_CR34","doi-asserted-by":"crossref","unstructured":"Olano-Soler H. Notes from the field: use of asynchronous video directly observed therapy for treatment of tuberculosis and latent tuberculosis infection in a long-term\u2013care facility \u2015 Puerto Rico, 2016\u20132017. MMWR Morb Mortal Wkly Rep; 2017. \n                    https:\/\/www.cdc.gov\/mmwr\/volumes\/66\/wr\/mm6650a5.htm\n                    \n                  . Accessed 2 Mar 2018.","DOI":"10.15585\/mmwr.mm6650a5"},{"key":"139_CR35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.drugalcdep.2018.01.015","volume":"186","author":"LA Lin","year":"2018","unstructured":"Lin LA, Lofwall MR, Walsh SL, Gordon AJ, Knudsen HK. Perceptions and practices addressing diversion among US buprenorphine prescribers. Drug Alcohol Depend. 2018;186:147\u201353.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"139_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1521-0391.2012.00335.x","volume":"22","author":"A Yang","year":"2013","unstructured":"Yang A, Arfken CL, Johanson C-E. Steps physicians report taking to reduce diversion of buprenorphine. Am J Addict. 2013;22(3):184\u20137.","journal-title":"Am J Addict"},{"issue":"4","key":"139_CR37","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1370\/afm.2099","volume":"15","author":"CHA Andrilla","year":"2017","unstructured":"Andrilla CHA, Coulthard C, Larson EH. Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Ann Fam Med. 2017;15(4):359\u201362.","journal-title":"Ann Fam Med"},{"key":"139_CR38","volume-title":"The discovery of grounded theory: strategies for qualitative research","author":"BG Glaser","year":"2009","unstructured":"Glaser BG, Strauss AL. The discovery of grounded theory: strategies for qualitative research. New Brunswick: Aldine; 2009."},{"key":"139_CR39","unstructured":"NVivo qualitative data analysis Software. QSR International Pty Ltd.; 2015."},{"key":"139_CR40","doi-asserted-by":"crossref","unstructured":"Bhatraju EP, Grossman E, Tofighi B, McNeely J, DiRocco D, Flannery M, et al. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7. Addict Sci Clin Pract; 2017. \n                    https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5331716\/\n                    \n                  . Accessed 6 Mar 2018.","DOI":"10.1186\/s13722-017-0072-2"},{"issue":"3","key":"139_CR41","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","volume":"46","author":"J Gryczynski","year":"2014","unstructured":"Gryczynski J, Mitchell SG, Jaffe JH, O\u2019Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: patients\u2019 reasons for cessation of care. J Subst Abuse Treat. 2014;46(3):356\u201361.","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"139_CR42","first-page":"472","volume":"25","author":"DE Marcovitz","year":"2016","unstructured":"Marcovitz DE, McHugh RK, Volpe J, Votaw V, Connery HS. Predictors of early dropout in outpatient buprenorphine\/naloxone treatment. Am J Addict Am Acad Psychiatr Alcohol Addict. 2016;25(6):472\u20137.","journal-title":"Am J Addict Am Acad Psychiatr Alcohol Addict"},{"issue":"1","key":"139_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0376-8716(00)00155-1","volume":"62","author":"ME McCaul","year":"2001","unstructured":"McCaul ME, Svikis DS, Moore RD. Predictors of outpatient treatment retention: patient versus substance use characteristics. Drug Alcohol Depend. 2001;62(1):9\u201317.","journal-title":"Drug Alcohol Depend"},{"key":"139_CR44","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.drugalcdep.2017.09.017","volume":"181","author":"CB Simon","year":"2017","unstructured":"Simon CB, Tsui JI, Merrill JO, Adwell A, Tamru E, Klein JW. Linking patients with buprenorphine treatment in primary care: predictors of engagement. Drug Alcohol Depend. 2017;181:58\u201362.","journal-title":"Drug Alcohol Depend"},{"issue":"11","key":"139_CR45","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/j.1525-1497.2005.0228.x","volume":"20","author":"MD Stein","year":"2005","unstructured":"Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20(11):1038\u201341.","journal-title":"J Gen Intern Med"},{"key":"139_CR46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jsat.2016.12.010","volume":"74","author":"ZM Weinstein","year":"2017","unstructured":"Weinstein ZM, Kim HW, Cheng DM, Quinn E, Hui D, Labelle CT, et al. Long-term retention in office based opioid treatment with buprenorphine. J Subst Abuse Treat. 2017;74:65\u201370.","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"139_CR47","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1080\/02791072.2014.921743","volume":"46","author":"C Teruya","year":"2014","unstructured":"Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, et al. Patient perspectives on buprenorphine\/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoact Drugs. 2014;46(5):412\u201326.","journal-title":"J Psychoact Drugs"},{"key":"139_CR48","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.2147\/DDDT.S72543","volume":"11","author":"RN Rosenthal","year":"2017","unstructured":"Rosenthal RN, Goradia VV. Advances in the delivery of buprenorphine for opioid dependence. Drug Des Devel Ther. 2017;11:2493\u2013505.","journal-title":"Drug Des Devel Ther"},{"key":"139_CR49","doi-asserted-by":"crossref","unstructured":"Gustafson DH, Landucci G, McTavish F, Kornfield R, Johnson RA, Mares M-L, et al. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial. Trials; 2016. \n                    https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5153683\/\n                    \n                  . Accessed 2 Mar 2018.","DOI":"10.1186\/s13063-016-1726-1"},{"key":"139_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jsat.2018.02.006","volume":"88","author":"D Liang","year":"2018","unstructured":"Liang D, Han H, Du J, Zhao M, Hser Y-I. A pilot study of a smartphone application supporting recovery from drug addiction. J Subst Abuse Treat. 2018;88:51\u20138.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"139_CR51","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/dar.12535","volume":"36","author":"B Tofighi","year":"2017","unstructured":"Tofighi B, Nicholson JM, McNeely J, Muench F, Lee JD. Mobile phone messaging for illicit drug and alcohol dependence: a systematic review of the literature. Drug Alcohol Rev. 2017;36(4):477\u201391.","journal-title":"Drug Alcohol Rev"},{"key":"139_CR52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.drugalcdep.2014.06.005","volume":"142","author":"TJ Cicero","year":"2014","unstructured":"Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. Factors contributing to the rise of buprenorphine misuse: 2008\u20132013. Drug Alcohol Depend. 2014;142:98\u2013104.","journal-title":"Drug Alcohol Depend"},{"issue":"17","key":"139_CR53","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1056\/NEJM200510273531724","volume":"353","author":"TJ Cicero","year":"2005","unstructured":"Cicero TJ, Inciardi JA. Potential for abuse of buprenorphine in office-based treatment of opioid dependence. N Engl J Med. 2005;353(17):1863\u20135.","journal-title":"N Engl J Med"},{"issue":"5","key":"139_CR54","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3109\/10550490903077820","volume":"18","author":"S Gwin Mitchell","year":"2009","unstructured":"Gwin Mitchell S, Kelly SM, Brown BS, Schacht Reisinger H, Peterson JA, Ruhf A, et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict. 2009;18(5):346\u201355.","journal-title":"Am J Addict"},{"key":"139_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","volume":"78","author":"AS Huhn","year":"2017","unstructured":"Huhn AS, Dunn KE. Why aren\u2019t physicians prescribing more buprenorphine? J Subst Abuse Treat. 2017;78:1\u20137.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"139_CR56","doi-asserted-by":"publisher","first-page":"644","DOI":"10.15288\/jsad.2015.76.644","volume":"76","author":"HK Knudsen","year":"2015","unstructured":"Knudsen HK. The supply of physicians waivered to prescribe buprenorphine for opioid use disorders in the united states: a state-level analysis. J Stud Alcohol Drugs. 2015;76(4):644\u201354.","journal-title":"J Stud Alcohol Drugs."},{"issue":"1","key":"139_CR57","doi-asserted-by":"publisher","first-page":"29","DOI":"10.5055\/jom.2012.0093","volume":"8","author":"TL Quest","year":"2012","unstructured":"Quest TL, Merrill JO, Roll J, Saxon AJ, Rosenblatt RA. Buprenorphine therapy for opioid addiction in rural Washington: the experience of the early adopters. J Opioid Manag. 2012;8(1):29\u201338.","journal-title":"J Opioid Manag"},{"key":"139_CR58","doi-asserted-by":"crossref","unstructured":"Holzman SB, Zenilman A, Shah M. Advancing patient-centered care in tuberculosis management: a mixed-methods appraisal of video directly observed therapy. Open Forum Infect Dis; 2018. \n                    https:\/\/academic.oup.com\/ofid\/article\/5\/4\/ofy046\/4924819\n                    \n                  . Accessed 26 Apr 2018.","DOI":"10.1093\/ofid\/ofy046"},{"issue":"2","key":"139_CR59","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7309\/jmtm.5.2.3","volume":"5","author":"ML Z\u00fa\u00f1iga","year":"2016","unstructured":"Z\u00fa\u00f1iga ML, Collins K, Mu\u00f1oz F, Moser K, Rangel G, Cuevas-Mota J, et al. A qualitative study exploring stakeholder perceptions of video directly observed therapy for monitoring tuberculosis treatment in the US-Mexico Border Region. J Mob Technol Med. 2016;5(2):12\u201323.","journal-title":"J Mob Technol Med"},{"issue":"1","key":"139_CR60","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"Y-I Hser","year":"2014","unstructured":"Hser Y-I, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addict Abingdon Engl. 2014;109(1):79\u201387.","journal-title":"Addict Abingdon Engl"}],"container-title":["Addiction Science & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-019-0139-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13722-019-0139-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-019-0139-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T14:39:04Z","timestamp":1589553544000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-019-0139-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,13]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["139"],"URL":"https:\/\/doi.org\/10.1186\/s13722-019-0139-3","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,13]]},"assertion":[{"value":"17 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"11"}}